GlobeNewswire by notified

Eurocastle announces results of Tender Offer, Company repurchases 864,980 shares at €10.26 per share, and Eurocastle to Release First Half 2022 Financial Results on 9 August 2022

Share

Eurocastle announces results of Tender Offer

Company repurchases 864,980 shares at €10.26 per share and

Eurocastle to Release First Half 2022 Financial Results on 9 August 2022

Guernsey, 5 August 2022 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today announces the results of the tender offer to repurchase up to 1,286,181 shares at a tender price of €10.26 per share (the “Tender Offer”). The circular describing the terms and conditions of the Tender Offer was published and made available to shareholders on 8 July 2022 (the “Circular”).

The Tender Offer closed at 6:00pm (CET) on 4 August 2022. In accordance with the terms and conditions set out in the Circular and based on the final count by the Company’s agent, ABN AMRO Bank N.V., Eurocastle accepted tenders of 864,980 Ordinary Shares at the fixed price of €10.26 per Ordinary Share for a total tender of €8.9 million, excluding fees and expenses relating to the Tender Offer. The shares accepted for repurchase represent approximately 47% of Ordinary Shares in issue as of 4 August 2022.

The record date for the tendered shares repurchased was 4 August 2022 with settlement expected by 9 August 2022 at which point the repurchased shares will be cancelled. As a consequence, as at 9 August 2022:

  • The total number of shares of the Company in issue will be 992,555;
  • The total number of shares held by Eurocastle in treasury will be nil (0% of the shares in issue);
  • The total number of voting rights exercisable by holders of shares of the Company will be 992,555; and
  • The FIG Concert Party will continue to hold 539,638 shares of the Company, representing approximately 54% of Ordinary Shares in issue.

The Company today also announces that it will release its financial results for the six months ended 30 June 2022 on Tuesday, 9 August 2022 before the market opens. Further details relating to the impact of the Tender Offer will be included in that announcement.

Any capitalised terms not defined in this announcement have the same meaning as in the Circular.

NOTICE: This announcement contains inside information for the purposes of the Market Abuse Regulation 596/2014.

ABOUT EUROCASTLE

Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. On 8 July 2022, the Company announced the relaunch of its investment activity with the aim to build a Southern European speciality finance and real estate platform. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Completion of capital reduction in Spar Nord Bank A/S26.4.2024 08:45:00 CEST | Press release

Company announcement no. 28 As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share capital by DKK 27,645,950 nominal value divided into 2,764,595 shares of DKK 10 through the cancellation of treasury shares. The capital reduction was published via the Danish Business Authority’s IT system on 26 March 2024. The statutory notice period has expired with no claims received. The capital reduction has been finally registered with the Danish Business Authority on 25 April 2024. After the capital reduction, the share capital of Spar Nord Bank A/S amounts to DKK 1,177,020,310 nominal value divided into shares of DKK 10 each. Pursuant to section 32 of the Danish Capital Markets Act, we hereby announce that the company’s total share capital and total number of voting rights amount to: Share capital (nominal value): DKK 1,177,020,310 Number of voting rights: 117,702,031 Please direct any questions rega

Gennemførelse af kapitalnedsættelse i Spar Nord Bank A/S26.4.2024 08:45:00 CEST | pressemeddelelse

Selskabsmeddelelse nr. 28 Som oplyst i selskabsmeddelelse nr. 22 blev det på Spar Nord Bank A/S’ ordinære generalforsamling den 19. marts 2024 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 27.645.950 fordelt i 2.764.595 aktier à DKK 10 ved annullation af egne aktier. Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 26. marts 2024. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er endeligt registreret den 25. april 2024 hos Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Spar Nord Bank A/S nominelt DKK 1.177.020.310 fordelt i aktier à DKK 10. I henhold til §32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til: Aktiekapital (nominelt): DKK 1.177.020.310 Antal stemmerettigheder: 117.702.031 Spørgsmål i forbindelse med denne meddelelse kan rettes til undertegnede på 96 34 42 36. Venlig hilsen Rune Brandt Børglum IR-

Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release

Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr

PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release

Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

HiddenA line styled icon from Orion Icon Library.Eye